Please login to the form below

Not currently logged in
Email:
Password:

Lilly's Zyprexa on 'deadly drugs' list

A study has found that Zyprexa has one of the highest rates of suspect drug deaths, ranking thirteenth on the list of drugs with the most reported deaths and adverse events

A study conducted by the Institute for Safe Medication Practices and the Division of Public Health Sciences at Wake Forest University School of Medicine has found that Zyprexa has one of the highest rates of suspect drug deaths, ranking thirteenth on the list of drugs with the most reported deaths and adverse events.

Over the eight years of the study, Zyprexa was linked to 1,005 deaths and 4,110 adverse events. The information was posted on the FDA's Adverse Event Reporting System and was published in the Archives of Internal Medicine in September.

An atypical antipsychotic, Zyprexa is approved to treat schizophrenia and bipolar disorder. Literature about the drug for medical professionals notes that suicide attempts are "inherent to schizophrenia and bipolar disorder", however.

Zyprexa posted FY06 sales of USD 4.4bn and is Lilly's best-selling product. It has, however, also caused huge legal problems. Lilly has paid more than USD 1bn to settle tens of thousands of patient lawsuits claiming the company failed to disclose that Zyprexa causes weight gain, diabetes complications and other health problems.

Several states are suing Lilly, claiming it marketed Zyprexa for off-label uses, including treatment of adolescents, dementia, depression and autism, without warning about its risks.

Since Zyprexa was launched in 1996, it has been prescribed to about 20 million people around the world. The drug loses patent protection in 2011.

In late September 2007, a three-member FDA team initially urged rejecting the drug for paediatric use because of inconsistent data from studies in US and Russian teens.

In a 29 April 2007 memo posted on the FDA's website, Thomas Laughren, head of the agency's psychiatry division, said the drug's benefits in some studies outweighed the reviewers' concerns.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics